AR038197A1 - Acidos 3-(imidazolil)-2-alcoxipropanoicos, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y uso de los mismos en la preparacion de medicamentos - Google Patents
Acidos 3-(imidazolil)-2-alcoxipropanoicos, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y uso de los mismos en la preparacion de medicamentosInfo
- Publication number
- AR038197A1 AR038197A1 ARP030100165A ARP030100165A AR038197A1 AR 038197 A1 AR038197 A1 AR 038197A1 AR P030100165 A ARP030100165 A AR P030100165A AR P030100165 A ARP030100165 A AR P030100165A AR 038197 A1 AR038197 A1 AR 038197A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- haloalkyl
- halo
- nr13r14
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto ácido 3-(imidazolil)-2-alcoxipropanoico de acuerdo con la fórmula (1), donde: n es 0, 1, 2 ó 3; R1 se selecciona entre; a) un grupo alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituida: b) un grupo alquenilo C2-6 de cadena lineal o ramificada opcionalmente sustituida, c) un grupo alquinilo C2-6 de cadena lineal o ramificada opcionalmente sustituida, d) arilo, e) heterociclo aromático, f) heterociclo, y g) H; estando los sustituyentes opcionales en los grupos (a), (b) y (c) anteriores seleccionados entre: cicloalquilo C3-7, arilo, heterociclo aromático, heterociclo, OR10, NR10R11, S(O)pR10, OC(O)R11, CO2R10, CONR10R11, SO2NR10R11, halo y NHSO2R10 y siendo p 0, 1, ó 2; cada uno de R2, R3, R4, R6, R7 y R9 se selecciona independientemente entre H y alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituida con OR10 o halo; cada uno de R5 y R8 se seleccionan independientemente entre H y alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituida con OR10 o halo, o tomados conjuntamente son una cadena alquileno C2-6; cada uno de R10 y R11 se selecciona independientemente entre H y alquilo C1-6 de cadena lineal o ramificada; arilo es un grupo monocíclico aromático o carbocíclico policíclico condensado de 6-14 miembros opcionalmente sustituido con uno o más grupos seleccionados entre R12, halo, OR13, NR13R14, NR13CO2R12, CO2R13, NR13SO2R12, CN, haloalquilo, O(haloalquilo), SR13, S(O)R12, SO2R12, OC(O)R13,SO2NR13R14 y C(O)NR13R14, cicloalquilo C3-7, O(cicloalquilo C3-7), R15 y OR15, siendo R12 alquilo C1-6 de cadena lineal o ramificada, seleccionándose cada uno de R13 y R14 independientemente entre H y alquilo C1-6 de cadena lineal o ramificada, y siendo R15 fenilo opcionalmente sustituido con R12, OR13, halo o haloalquilo; heterociclo aromático es un anillo aromático de 5 a 7 miembros que contiene de 1 a 3 heteroátomos, seleccionándose cada uno independientemente entre O, S; y N, estando dicho anillo opcionalmente sustituido con uno o más grupos seleccionados entre OR13, NR13R14, CO2R13, NR13CO2R12, R12, halo, CN, haloalquilo, O(haloalquilo), SR13, S(O)R12, SO2R12, OC(O)R13, NR13SO2R12, SO2NR13R14 y C(O)NR13R14,y heterociclo es un anillo de 3 a 8 miembros que contiene de 1 a 3 heteroátomos, cada uno seleccionado independientemente entre O, S, y N, estando dicho anillo saturado o parcialmente saturado, estando además dicho anillo opcionalmente sustituido con uno o más grupos seleccionados entre OR13, NR13R14, CO2R13,NR13CO2R14, R12, halo, CN, haloalquilo, O(haloalquilo), SR13, S(O)R12, SO2R12, OC(O)R13, NR13SO2R12, SO2NR13R14 y C(O)NR13R14, o un tautómero del mismo o una sal farmacéuticamente aceptable de dicho compuesto o de dicho tautómero. Procedimientos para la preparación de los mismos, composiciones farmacéuticas que los contienen, y uso de los mismos en la preparación de medicamentos útiles para tratar trastornos cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201389A GB0201389D0 (en) | 2002-01-22 | 2002-01-22 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| GB0202027A GB0202027D0 (en) | 2002-01-29 | 2002-01-29 | 3-(imidazolyl)-2-alkoxypropanoic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038197A1 true AR038197A1 (es) | 2005-01-05 |
Family
ID=27614792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100165A AR038197A1 (es) | 2002-01-22 | 2003-01-21 | Acidos 3-(imidazolil)-2-alcoxipropanoicos, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y uso de los mismos en la preparacion de medicamentos |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1467731A1 (es) |
| JP (1) | JP2005520811A (es) |
| KR (1) | KR20040077775A (es) |
| CN (1) | CN1620291A (es) |
| AP (1) | AP2004003084A0 (es) |
| AR (1) | AR038197A1 (es) |
| BR (1) | BR0307016A (es) |
| CA (1) | CA2472238A1 (es) |
| EA (1) | EA200400716A1 (es) |
| EC (1) | ECSP045200A (es) |
| HR (1) | HRP20040659A2 (es) |
| IL (1) | IL162677A0 (es) |
| IS (1) | IS7310A (es) |
| MA (1) | MA27167A1 (es) |
| MX (1) | MXPA04006573A (es) |
| NO (1) | NO20043457L (es) |
| OA (1) | OA12756A (es) |
| PA (1) | PA8563501A1 (es) |
| PE (1) | PE20030929A1 (es) |
| PL (1) | PL371487A1 (es) |
| TN (1) | TNSN04121A1 (es) |
| TW (1) | TW200302094A (es) |
| UY (1) | UY27615A1 (es) |
| WO (1) | WO2003061652A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| US20060234986A1 (en) * | 2005-04-18 | 2006-10-19 | Schering Aktiengesellschaft | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI |
| WO2010050525A1 (ja) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
| TW201033184A (en) | 2008-12-05 | 2010-09-16 | Mochida Pharm Co Ltd | Morpholinone compounds as factor IXa inhibitors |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| JP5778133B2 (ja) * | 2010-03-18 | 2015-09-16 | 第一三共株式会社 | シクロプロパンカルボン酸誘導体 |
| CN102803226B (zh) | 2010-03-18 | 2016-05-04 | 第一三共株式会社 | 环烷基取代的咪唑衍生物 |
| US9834527B2 (en) | 2013-06-10 | 2017-12-05 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
| JPWO2017170460A1 (ja) | 2016-03-29 | 2019-02-07 | 第一三共株式会社 | 炎症性腸疾患治療剤 |
| EP3682881A4 (en) | 2017-09-14 | 2021-08-11 | Daiichi Sankyo Company, Limited | CONNECTION WITH CYCLICAL STRUCTURE |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| PT1311488E (pt) * | 2000-08-17 | 2009-12-30 | Pfizer Ltd | Imidazóis substituídos utilizados como inibidores de tafia |
-
2003
- 2003-01-10 JP JP2003561596A patent/JP2005520811A/ja active Pending
- 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
- 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/en not_active Application Discontinuation
- 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/es unknown
- 2003-01-10 IL IL16267703A patent/IL162677A0/xx unknown
- 2003-01-10 CA CA002472238A patent/CA2472238A1/en not_active Abandoned
- 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/ko not_active Application Discontinuation
- 2003-01-10 CN CNA03802599XA patent/CN1620291A/zh active Pending
- 2003-01-10 EP EP03700059A patent/EP1467731A1/en not_active Withdrawn
- 2003-01-10 BR BR0307016-6A patent/BR0307016A/pt not_active IP Right Cessation
- 2003-01-10 PL PL03371487A patent/PL371487A1/xx unknown
- 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
- 2003-01-10 EA EA200400716A patent/EA200400716A1/ru unknown
- 2003-01-16 TW TW092100889A patent/TW200302094A/zh unknown
- 2003-01-17 PE PE2003000058A patent/PE20030929A1/es not_active Application Discontinuation
- 2003-01-20 UY UY27615A patent/UY27615A1/es not_active Application Discontinuation
- 2003-01-21 AR ARP030100165A patent/AR038197A1/es unknown
- 2003-01-22 PA PA20038563501A patent/PA8563501A1/es unknown
-
2004
- 2004-06-14 IS IS7310A patent/IS7310A/is unknown
- 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
- 2004-07-15 MA MA27786A patent/MA27167A1/fr unknown
- 2004-07-19 HR HR20040659A patent/HRP20040659A2/hr not_active Application Discontinuation
- 2004-07-22 EC EC2004005200A patent/ECSP045200A/es unknown
- 2004-08-19 NO NO20043457A patent/NO20043457L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1467731A1 (en) | 2004-10-20 |
| OA12756A (en) | 2006-07-03 |
| IL162677A0 (en) | 2005-11-20 |
| KR20040077775A (ko) | 2004-09-06 |
| CA2472238A1 (en) | 2003-07-31 |
| CN1620291A (zh) | 2005-05-25 |
| EA200400716A1 (ru) | 2004-12-30 |
| JP2005520811A (ja) | 2005-07-14 |
| TNSN04121A1 (en) | 2006-06-01 |
| HRP20040659A2 (en) | 2004-10-31 |
| TW200302094A (en) | 2003-08-01 |
| UY27615A1 (es) | 2003-08-29 |
| PL371487A1 (en) | 2005-06-13 |
| PA8563501A1 (es) | 2004-08-31 |
| MXPA04006573A (es) | 2004-10-04 |
| AP2004003084A0 (en) | 2004-09-30 |
| BR0307016A (pt) | 2004-11-03 |
| MA27167A1 (fr) | 2005-01-03 |
| WO2003061652A1 (en) | 2003-07-31 |
| WO2003061652A8 (en) | 2004-09-10 |
| ECSP045200A (es) | 2004-08-27 |
| PE20030929A1 (es) | 2003-11-05 |
| IS7310A (is) | 2004-06-14 |
| NO20043457L (no) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032781A1 (es) | Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| CO5690588A2 (es) | Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| AR033408A1 (es) | Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen | |
| AR048934A1 (es) | Morfolinas | |
| NO20053460L (no) | Nye forbindelser med selektiv inhibiterende effekt ved GSK3 | |
| AR045255A1 (es) | Derivados de 1,2 benzodiazol | |
| EA200000481A1 (ru) | Производные гидроксамовой кислоты в качестве ингибиторов металлопротеаз матрикса (мпм) | |
| AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
| MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| MXPA02002720A (es) | Nuevos compuestos de alfa-aminoacido-sulfonilo, un proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
| AR036045A1 (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, su empleo para la preparacion de un medicamento, asi como composiciones farmaceuticas que las contienen | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| EA200900279A1 (ru) | Арилсульфонамиды с аналгетическим действием | |
| AR038197A1 (es) | Acidos 3-(imidazolil)-2-alcoxipropanoicos, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y uso de los mismos en la preparacion de medicamentos | |
| ES2255190T3 (es) | Compuestos indol 2,3-sustituidos como inhibidores de cox-2. | |
| AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
| AR050260A1 (es) | Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| AR057525A1 (es) | Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion | |
| AR017256A1 (es) | Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
| PE20011183A1 (es) | Metabolitos agonistas/antagonistas de estrogeno | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |